Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review
Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibi...
Gespeichert in:
| Veröffentlicht in: | Acta dermato-venereologica 2012-01, Vol.92 (5), p.555-560 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 560 |
|---|---|
| container_issue | 5 |
| container_start_page | 555 |
| container_title | Acta dermato-venereologica |
| container_volume | 92 |
| creator | Phan, Ngoc Quan Lotts, Tobias Antal, Attila Bernhard, Jeffrey D Ständer, Sonja |
| description | Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus in both animals and humans. The antipruritic effect of kappa-opioid receptors agonists can currently be assumed to be related to their binding to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. To date, several case reports and 2 controlled trials have demonstrated a beneficial effect of systemic kappa-opioid receptor agonists in the treatment of uraemic pruritus, prurigo nodularis, paraneoplastic and cholestatic pruritus. Nalfurafine hydrochloride (Remitch(®)), a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan. The aim of this review is to provide an overview of the promising role of kappa- opioid receptors and their agonist in the pathophysiology and treatment of pruritus. |
| doi_str_mv | 10.2340/00015555-1353 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1111856601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1111856601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-8195583e44a45dfcf9e1aafa73563b20ceb6c50beea372cb0f72642aa3f344f03</originalsourceid><addsrcrecordid>eNo9kDtPwzAUhS0EoqUwsiKPLAE_k5QNIV5SJQZgjm7ca2pI4mA7oP57UrXlLFdX59MZPkLOObsSUrFrxhjXYzIutTwgU55rngmmi0My3XTZppyQkxg_x1doXh6TiRCaqYLNpwRe1zFh6wz9gr4H6nvn3ZIGNNgnHyh8-M7FFKnraFohTQEhtdgl6i01qzC2hvZhCC4N8YYCbVzCAGkIOI78OPw9JUcWmohnuzsj7w_3b3dP2eLl8fnudpEZJWTKSj7XupSoFCi9tMbOkQNYKKTOZS2YwTo3mtWIIAthamYLkSsBIK1UyjI5I5fb3T747wFjqloXDTYNdOiHWPExpc5zxkc026Im-BgD2qoProWwrjirNlarvdVqY3XkL3bTQ93i8p_ea5R_dxZzEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1111856601</pqid></control><display><type>article</type><title>Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review</title><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ）</source><source>Alma/SFX Local Collection</source><creator>Phan, Ngoc Quan ; Lotts, Tobias ; Antal, Attila ; Bernhard, Jeffrey D ; Ständer, Sonja</creator><creatorcontrib>Phan, Ngoc Quan ; Lotts, Tobias ; Antal, Attila ; Bernhard, Jeffrey D ; Ständer, Sonja</creatorcontrib><description>Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus in both animals and humans. The antipruritic effect of kappa-opioid receptors agonists can currently be assumed to be related to their binding to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. To date, several case reports and 2 controlled trials have demonstrated a beneficial effect of systemic kappa-opioid receptor agonists in the treatment of uraemic pruritus, prurigo nodularis, paraneoplastic and cholestatic pruritus. Nalfurafine hydrochloride (Remitch(®)), a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan. The aim of this review is to provide an overview of the promising role of kappa- opioid receptors and their agonist in the pathophysiology and treatment of pruritus.</description><identifier>ISSN: 0001-5555</identifier><identifier>EISSN: 1651-2057</identifier><identifier>DOI: 10.2340/00015555-1353</identifier><identifier>PMID: 22504709</identifier><language>eng</language><publisher>Sweden</publisher><subject>Animals ; Antipruritics - therapeutic use ; Butorphanol - therapeutic use ; Chronic Disease ; Humans ; Morphinans - therapeutic use ; Pruritus - diagnosis ; Pruritus - drug therapy ; Pruritus - metabolism ; Receptors, Opioid, kappa - agonists ; Receptors, Opioid, kappa - metabolism ; Spiro Compounds - therapeutic use ; Treatment Outcome</subject><ispartof>Acta dermato-venereologica, 2012-01, Vol.92 (5), p.555-560</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-8195583e44a45dfcf9e1aafa73563b20ceb6c50beea372cb0f72642aa3f344f03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22504709$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Phan, Ngoc Quan</creatorcontrib><creatorcontrib>Lotts, Tobias</creatorcontrib><creatorcontrib>Antal, Attila</creatorcontrib><creatorcontrib>Bernhard, Jeffrey D</creatorcontrib><creatorcontrib>Ständer, Sonja</creatorcontrib><title>Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review</title><title>Acta dermato-venereologica</title><addtitle>Acta Derm Venereol</addtitle><description>Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus in both animals and humans. The antipruritic effect of kappa-opioid receptors agonists can currently be assumed to be related to their binding to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. To date, several case reports and 2 controlled trials have demonstrated a beneficial effect of systemic kappa-opioid receptor agonists in the treatment of uraemic pruritus, prurigo nodularis, paraneoplastic and cholestatic pruritus. Nalfurafine hydrochloride (Remitch(®)), a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan. The aim of this review is to provide an overview of the promising role of kappa- opioid receptors and their agonist in the pathophysiology and treatment of pruritus.</description><subject>Animals</subject><subject>Antipruritics - therapeutic use</subject><subject>Butorphanol - therapeutic use</subject><subject>Chronic Disease</subject><subject>Humans</subject><subject>Morphinans - therapeutic use</subject><subject>Pruritus - diagnosis</subject><subject>Pruritus - drug therapy</subject><subject>Pruritus - metabolism</subject><subject>Receptors, Opioid, kappa - agonists</subject><subject>Receptors, Opioid, kappa - metabolism</subject><subject>Spiro Compounds - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0001-5555</issn><issn>1651-2057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAUhS0EoqUwsiKPLAE_k5QNIV5SJQZgjm7ca2pI4mA7oP57UrXlLFdX59MZPkLOObsSUrFrxhjXYzIutTwgU55rngmmi0My3XTZppyQkxg_x1doXh6TiRCaqYLNpwRe1zFh6wz9gr4H6nvn3ZIGNNgnHyh8-M7FFKnraFohTQEhtdgl6i01qzC2hvZhCC4N8YYCbVzCAGkIOI78OPw9JUcWmohnuzsj7w_3b3dP2eLl8fnudpEZJWTKSj7XupSoFCi9tMbOkQNYKKTOZS2YwTo3mtWIIAthamYLkSsBIK1UyjI5I5fb3T747wFjqloXDTYNdOiHWPExpc5zxkc026Im-BgD2qoProWwrjirNlarvdVqY3XkL3bTQ93i8p_ea5R_dxZzEg</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Phan, Ngoc Quan</creator><creator>Lotts, Tobias</creator><creator>Antal, Attila</creator><creator>Bernhard, Jeffrey D</creator><creator>Ständer, Sonja</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review</title><author>Phan, Ngoc Quan ; Lotts, Tobias ; Antal, Attila ; Bernhard, Jeffrey D ; Ständer, Sonja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-8195583e44a45dfcf9e1aafa73563b20ceb6c50beea372cb0f72642aa3f344f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antipruritics - therapeutic use</topic><topic>Butorphanol - therapeutic use</topic><topic>Chronic Disease</topic><topic>Humans</topic><topic>Morphinans - therapeutic use</topic><topic>Pruritus - diagnosis</topic><topic>Pruritus - drug therapy</topic><topic>Pruritus - metabolism</topic><topic>Receptors, Opioid, kappa - agonists</topic><topic>Receptors, Opioid, kappa - metabolism</topic><topic>Spiro Compounds - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Phan, Ngoc Quan</creatorcontrib><creatorcontrib>Lotts, Tobias</creatorcontrib><creatorcontrib>Antal, Attila</creatorcontrib><creatorcontrib>Bernhard, Jeffrey D</creatorcontrib><creatorcontrib>Ständer, Sonja</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta dermato-venereologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Phan, Ngoc Quan</au><au>Lotts, Tobias</au><au>Antal, Attila</au><au>Bernhard, Jeffrey D</au><au>Ständer, Sonja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review</atitle><jtitle>Acta dermato-venereologica</jtitle><addtitle>Acta Derm Venereol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>92</volume><issue>5</issue><spage>555</spage><epage>560</epage><pages>555-560</pages><issn>0001-5555</issn><eissn>1651-2057</eissn><abstract>Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus in both animals and humans. The antipruritic effect of kappa-opioid receptors agonists can currently be assumed to be related to their binding to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. To date, several case reports and 2 controlled trials have demonstrated a beneficial effect of systemic kappa-opioid receptor agonists in the treatment of uraemic pruritus, prurigo nodularis, paraneoplastic and cholestatic pruritus. Nalfurafine hydrochloride (Remitch(®)), a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan. The aim of this review is to provide an overview of the promising role of kappa- opioid receptors and their agonist in the pathophysiology and treatment of pruritus.</abstract><cop>Sweden</cop><pmid>22504709</pmid><doi>10.2340/00015555-1353</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5555 |
| ispartof | Acta dermato-venereologica, 2012-01, Vol.92 (5), p.555-560 |
| issn | 0001-5555 1651-2057 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1111856601 |
| source | MEDLINE; Free E-Journal (出版社公開部分のみ）; Alma/SFX Local Collection |
| subjects | Animals Antipruritics - therapeutic use Butorphanol - therapeutic use Chronic Disease Humans Morphinans - therapeutic use Pruritus - diagnosis Pruritus - drug therapy Pruritus - metabolism Receptors, Opioid, kappa - agonists Receptors, Opioid, kappa - metabolism Spiro Compounds - therapeutic use Treatment Outcome |
| title | Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20kappa%20opioid%20receptor%20agonists%20in%20the%20treatment%20of%20chronic%20pruritus:%20a%20literature%20review&rft.jtitle=Acta%20dermato-venereologica&rft.au=Phan,%20Ngoc%20Quan&rft.date=2012-01-01&rft.volume=92&rft.issue=5&rft.spage=555&rft.epage=560&rft.pages=555-560&rft.issn=0001-5555&rft.eissn=1651-2057&rft_id=info:doi/10.2340/00015555-1353&rft_dat=%3Cproquest_cross%3E1111856601%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1111856601&rft_id=info:pmid/22504709&rfr_iscdi=true |